James M Kovacs

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11973148/publications.pdf

Version: 2024-02-01

17	1,035	14	17
papers	citations	h-index	g-index
17	17	17	1681 citing authors
all docs	docs citations	times ranked	

#	Article	IF	CITATIONS
1	HIV-1 envelope trimer elicits more potent neutralizing antibody responses than monomeric gp120. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 12111-12116.	7.1	163
2	HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design. Cell Host and Microbe, 2019, 25, 59-72.e8.	11.0	124
3	Determination of intrinsic hydrophilicity/hydrophobicity of amino acid side chains in peptides in the absence of nearest-neighbor or conformational effects. Biopolymers, 2006, 84, 283-297.	2.4	123
4	Intrinsic amino acid sideâ€chain hydrophilicity/hydrophobicity coefficients determined by reversedâ€phase highâ€performance liquid chromatography of model peptides: Comparison with other hydrophilicity/hydrophobicity scales. Biopolymers, 2009, 92, 573-595.	2.4	114
5	Effect of the cytoplasmic domain on antigenic characteristics of HIV-1 envelope glycoprotein. Science, 2015, 349, 191-195.	12.6	113
6	Detection of complement activation using monoclonal antibodies against C3d. Journal of Clinical Investigation, 2013, 123, 2218-2230.	8.2	78
7	Stable, uncleaved HIV-1 envelope glycoprotein gp140 forms a tightly folded trimer with a native-like structure. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 18542-18547.	7.1	67
8	Requirements for prediction of peptide retention time in reversed-phase high-performance liquid chromatography: Hydrophilicity/hydrophobicity of side-chains at the N- and C-termini of peptides are dramatically affected by the end-groups and location. Journal of Chromatography A, 2007, 1141, 212-225.	3.7	50
9	A Multivalent Clade C HIV-1 Env Trimer Cocktail Elicits a Higher Magnitude of Neutralizing Antibodies than Any Individual Component. Journal of Virology, 2015, 89, 2507-2519.	3.4	42
10	Design of Lipid Nanocapsule Delivery Vehicles for Multivalent Display of Recombinant Env Trimers in HIV Vaccination. Bioconjugate Chemistry, 2014, 25, 1470-1478.	3.6	38
11	Characterization and Immunogenicity of a Novel Mosaic M HIV-1 gp140 Trimer. Journal of Virology, 2014, 88, 9538-9552.	3.4	30
12	Mapping of the C3d Ligand Binding Site on Complement Receptor 2 (CR2/CD21) Using Nuclear Magnetic Resonance and Chemical Shift Analysis. Journal of Biological Chemistry, 2009, 284, 9513-9520.	3.4	28
13	Delineation of the Complement Receptor Type 2–C3d Complex by Site-Directed Mutagenesis and Molecular Docking. Journal of Molecular Biology, 2010, 404, 697-710.	4.2	24
14	Quantitation of the nearest-neighbour effects of amino acid side-chains that restrict conformational freedom of the polypeptide chain using reversed-phase liquid chromatography of synthetic model peptides with I- and d-amino acid substitutions. Journal of Chromatography A, 2006, 1123, 212-224.	3.7	20
15	Biophysical Investigations of Complement Receptor 2 (CD21 and CR2)-Ligand Interactions Reveal Amino Acid Contacts Unique to Each Receptor-Ligand Pair. Journal of Biological Chemistry, 2010, 285, 27251-27258.	3.4	10
16	Neutralizing Antibody Responses following Long-Term Vaccination with HIV-1 Env gp140 in Guinea Pigs. Journal of Virology, 2018, 92, .	3.4	10
17	Characterizing the complement receptor Type 2–C3d complex by site-directed mutagenesis and molecular modeling. Molecular Immunology, 2010, 47, 2258-2258.	2.2	1